+34 620 10 75 37info@nanbiosis.com

News U2

News U2

NANBIOSIS in the Posters presentation in CIBER-BBN ANNUAL CONFERENCE 2018

Last 12 and 13 of November, CIBER-BBN  has celebrated its 12th Annual Conference in Hotel Felipe IV in Valladolid. In poster session participated  NANBIOSIS  itself and some of its units.

  • NANBIOSIS, Infrastructure for the Production & Characterization of Biomaterials, Nanomaterials and medical devices up to preclinical validation. Nanbiosis management team.
  • Divalent cation effects on assembly of histidine-rich protein nanoparticles. López-Laguna, U. Unzueta, O. Conchillo-Solé, A. Sánchez-Chardi, M. Pesarrodona, O. Cano-Garrido, E. Voltà, L. Sánchez-García, N. Serna, P. Saccardo, R. Mangues, A. Villaverde, E. Vázquez (NBT-UAB) (U1 -U18)
  • Antimicrobial peptides (AMPs) anchored on the surface of contact lenses to prevent corneal infections. Emiliano Salvagni, Clara García, Àngels Manresa, Carlos Rodríguez, María José García-Celma, Claudia Müller-Sánchez, Manuel Reina, Jordi Esquena (QCI-CSIC) (U12)
  • Preliminary studies on ultrasound characterization of perfluorocarbon-loaded polymeric nanocapsules. Gabriela Calderó, Marie Pierre Krafft, Da Shi, María José García-Celma, Conxita Solans, Carlos Rodríguez-Abreu (QCI-CSIC) (U12)
  • Multiplexed analytical platforms based on the use of antibodies for monitoring pollutants in marine environment samples. -Pablo Salvador, Ana Sanchís, Klaudia Kooper, Andrea Miti, M.-Pilar Marco (Nb4D-IQAC-CSIC) (U2)
  • In vitrodiagnostics of neurological disorders through the immunochemical detection of kynurenine. Montserrat Rodríguez Núñez, Ana Sanchís, Lluïsa Vilaplana, Roger Galve, M.-Pilar Marco (Nb4D-IQAC-CSIC) (U2)
  • Custom Antibody Service: From the molecule to the bioassay. Núria Pascual, Ana González-Gomzález, M.-Pilar Marco (Nb4D-IQAC-CSIC) (U2)
  • Hyaluronic acid enhances insulin release of microencapsulated pancreatic progenitors differentiated from mesenchymal stem cells. Alberto Cañibano-Hernández, Laura Sáenz del Burgo, Albert Espona-Noguera, Gorka Orive, Rosa María Hernández, Jesús Ciriza, Jose Luis Pedraz (NANOBIOCEL) (U10 )
  • Type 1 Diabetes Mellitus reversal via implantation of magnetically purified microencapsulated pseudoislets. Albert Espona-Noguera, J. Etxebarria-Elezgarai, L. Saenz del Burgo, A. Cañibano-Hernández, H. Gurruchaga, Gorka Orive, Rosa M. Hernández, F. Benito-Lopez, J. Ciriza, L. Basabe-Desmonts and J.L. Pedraz (NANOBIOCEL) (U10 )
  • Unraveling the immune system participation in therapy response in GL261 glioblastoma: correlation with MRSI-based molecular imaging techniques. Calero, N. Arias-Ramos, R. Rabanal, M. Pumarola, C. Arús, A.P. Candiota (GABRMN-UAB) (U25)
  • Dual T1/T2 nanoscale coordination polymers as novel contrast agents for MRI: a preclinical study for brain tumor. Suárez-García, N. Arias-Ramos, C. Frias, A.P. Candiota, C. Arús, J. Lorenzo, D. Ruiz-Molina, F. Novio (GABRMN-UAB) (U25)
  • Impact of high glucose levels and ketoacidosis associated to diabetic complications on bacterial growth and attachment to Ti6Al4V. Miguel A. Pacha-Olivenza, María Fernández-Grajera, Daniel Romero-Guzmán, M. Luisa González-Martín (AM-UEX) (U16)
  • Preparation, characterization and bacterial performance on PLDA and PLDA 10% Mg films. Verónica Luque-Agudo, Daniel Romero-Guzmán, Coronada Fernández-Calderón, Miguel A. Pacha-Olivenza, María Fernández-Grajera, Margarita Hierro-Oliva, M. Luisa Navarro-Pérez, Ciro Pérez-Giraldo, M. Luisa González-Martín, Amparo M. Gallardo-Moreno (AM-UEX) (U16)
  • A wavelet-based approach for automatic diagnosis of strict left bundle branch block. Alba Martín-Yebra, Juan Pablo Martínez (BSICoS) (U27)
  • ECG-derived respiration in atrial fibrillation. Spyridon Kontaxis, Jesús Lázaro, Valentina D. A. Corino, Frida Sandberg, Raquel Bailón, Pablo Laguna, and Leif Sörnmo (BSICoS) (U27)
  • Development of highly metastatic, CXCR4-overexpressing, colorectal cancer models. Rita Sala, Alberto Gallardo, Ugutz Unzueta, Patricia Álamo, Carmen Cabrera, Esperanza Medina, Isolda Casanova, Irene Arroyo, Aïda Falgás, Carlos Navas, Manuel Trías, Antonio Villaverde, Esther Vázquez, Ramón Mangues, Mª Virtudes Céspedes (GOA-HSPau) (U18)
  • PATHGATE: Oligonucleotide-gated sensing nanodevices for pathogen detection. Luis Pla, Angela Ribes, M. Angeles Tormo-Mas, Javier Pemán, Félix Sancenón, Elena Aznar, Ramón Martínez-Máñez and Sara Santiago-Felipe (IQMA-IDM-UPV) (U26)
  • Towards chemical communication between abiotic nanoparticles and living systems. Beatriz de Luis, Paola Ricón, Cristina de la Torre, Antoni LLopis, Jose Gadea, Jose R. Murguía, Félix Sancenón, Ramón Martínez-Máñez, Elena Aznar (IQMA-IDM-UPV) (U26)
  • Development  and  in vitro evaluation  of  antimicrobial  polymer  coatings  for the prophylactic treatment of hernia repair materials. Bárbara Pérez-Köhler, Selma Benito, Mar Fernández-Gutiérrez, Gemma Pascual, Marta Rodríguez, Verónica Gómez-Gil, Francisca García-Moreno, Julio San Román, Juan Manuel Bellón (GITBIT-UAH) (U17)
  • Experimental study of the application of a new bone cement loaded with broad spectrum antibiotics for the treatment of bone infection. Joaquín García, Galo Azuara, Blanca Ibarra, Miguel A. Ortega, Ángel Asúnsolo, Blanca Vázquez, Julio San Román, Julia Buján, Basilio De la Torre, Natalio García-Honduvilla (GITBIT-UAH) (U17)
Read More

Nanoplasmonic biosensor device for the monitoring of acenocoumarol therapeutic drug in plasma

As a result of the collaboration carried aout by two units of NANBIOSIS, U4. Biodeposition and Biodetection Unit and U2. Custom Antibody Service (CAbS), it has been developed a compact and simple nanoplasmonic sensing device based on gold nanodisks for the rapid monitoring of acenocoumarol, using highly specific polyclonal antibodies produced against the drug Acenocoumarol (Sintrom®) which implies:

  • A label-free nanoplasmonic device for the rapid monitoring of acenocoumarol in plasmaD.
  • Direct quantification in real time requiring low sample volume is achieved.
  • Non-specific interferences from plasma are minimized using the developed methodology.
  • Excellent accuracy has been observed measuring blind plasma samples.
  • Potential to be implemented as a POC device in decentralized settings.

 

The research details have been published in the article authored by E. CristinaPeláezM.-CarmenEstevezAlejandroPortelaJ.-PabloSalvadorM.-PilarMarco and Laura M.Lechuga, “Nanoplasmonic biosensor device for the monitoring of acenocoumarol therapeutic drug in plasma, Biosensors and Bioelectronic, 119, 2018, 149-155 – DOI: https://doi.org/10.1016/j.bios.2018.08.011

 

Read More

Interferometric nanoimmunosensor for label-free and real-time monitoring of Irgarol 1051 in seawater

As a result of a collaboration in the context of the EC-FP7 program OCEAN 2013, NANBIOSIS Unit 2 Custom Antibody Service (CAbS) and  Unit 4. Biodeposition and Biodetection,  the research groups coordinating this NANBIOSIS Units have recently published an article titled “Interferometric nanoimmunosensor for label-free and real-time monitoring of Irgarol 1051 in seawater” in the scientific magzine  iosensors and Bioelectronics.

The CIBER-BBN-ICN2 group  Nanobiosensors and Bioanalytical Applications, led by Prof. Laura Lechuga has developed the immunosensor that is described in the article using immunoreactive, produced in the group of  Nanobiotechnology for Diagnostics Group (Nb4D), led by Prof. Pilar Marco, with the collaboration of CAbS, for Irgarol 1051. This compound is an alguicide used as an additive in the paintings of ships. Over time, the compose is being released  into the marine environment causing a risk to the ecosystem and to the health of the population.

In the article, an interferometric nanobiosensor for the specific and label-free detection of the pollutant Irgarol 1051 directly in seawater has been settled. Due to the low molecular weight of Irgarol pollutant and its expected low concentration in seawater, the sensor is based on a competitive inhibition immunoassay. Parameters as surface biofunctionalization, concentration of the selective antibody and regeneration conditions have been carefully evaluated. The optimized immunosensor shows a limit of detection of only 3 ng/L, well below the 16 ng/L set by the EU as the maximum allowable concentration in seawater. It can properly operate during 30 assay-regeneration cycles using the same sensor biosurface and with a time-to-result of only 20 min for each cycle. Moreover, the interferometric nanosensor is able to directly detect low concentrations of Irgarol 1051 in seawater without requiring sample pre-treatments and without showing any background signal due to sea matrix effect.

Article of referencehttps://doi.org/10.1016/j.bios.2018.05.044

Read More

NANBIOSIS U2 incorporates a new Nitrogen tank to store cells

NANBIOSIS U2. Custom Antibody Service (CAbS), is incorporating new equipment as a result of its participation in the project FICTS1420-27, selected by the MINECO for co-financing by the FEDER Program in ICTS 2014-2020.

Recently the purchase and installation and set-up of a new nitrogen tank to store cells has taken place. The storage of cell lines of monoclonal antibody-producing hybridomas is a process in which the cells are conserved when they are cooled to temperatures typically at -196 ° C in liquid Nitrogen tanks. With temperatures below -130 ° C the activity Biological ceases and storage at these temperatures is vital to keep the material unaltered. The increasing activity of the NANBIOSIS U2 the makes necesary to incorporate a new tank of liquid Nitrogen for the storage of new hybridoma lines.

For further information:

 

Liquid nitrogen tank
Read More

Agreements signed with MINECO for the allocation of FEDER funds for NANBIOSIS ICTS

In the framework of the FEDER Program in ICTS 2014-2020, several projects related to the ICTS NANBIOSIS have been selected by the MINECO for co-financing with FEDER funds of the European Regional Development Funds program.

An agreement has been signed between MINECO and CIBER (partner of NANBIOSIS for the co-financing of the Project: “Purchase, installation and set-up of production and characterization equipment to complement the Units: U3-Synthesis of Peptides Unit, U18-Nanotoxicology and U20- In Vivo Experimental Platform”. The total budget of the project amounts to € 307,566.16, with 50% financing with FEDER Funds.

Also CSIC (The State Agency Superior Council of Scientific Investigations), institution that houses some of the NANBIOSIS units,  as distributed ICTS,  has signed an agreement with MINECO for the co-financing of the Project: “Purchase and installation and set-up of equipment and production and characterization laboratories to complement the units U2-Production of antibodies, U4-Biodeposition and biosensing, U6-Processing of biomaterials and U8-Micro, nanotechnology. The total budget of the project amounts to € 312.800,00 €, with 50% financing with FEDER Funds.

These two projects aim to increase the quantity and quality of the services offered by th implied units, with the objetive of positioning them as national and international benchmark in their respective fields of application. As a consequence, an increase in the performance (number of services and number of users) of each unit is expected, especially from companies (pharmaceutical and small biotechnology).

CSIC and CIBER are processing the necessary contracting procedures for the execution of these projects.

Read More

How to validate your favourite antibodies?

Are you interested in learning how to validate your favourite antibodies?

Do not miss the opportunity to attend the 4th EuroMAbNet Antibody Validation Workshop!

The Antibody Validation Workshop brings together highly specialized scientists in monoclonal antibody (mAbs) technology with PhD students and young scientists who are using antibodies in their research projects. The workshop will provide a set of criteria and recommendations that will help you to select the most effective mAbs from those available in the market and provide the strategic guidance needed to perform any essential antibody validation. This includes verifying antibody specificity, selectivity, sensitivity and reproducibility.

Nuria Pascual, Scientific Coordinator of NANBIOSIS U2, Custom Antibody Service (CAbS), is member of EUROMABNET and member of  organizing committee of the antibody validation workshop

Click  here to see the program of the, 4th EuroMAbNet Antibody Validation Workshop, 1st of July 2018, University of Ghent’s Congress Center, Ghent , Belgium. The 4th EuroMAbNet Antibody Validation Workshop will be held as a satellite event within the Core Technologies for Life Sciences (CTLS) meeting 2018.

Register  here before the 20th of June

 

  • Registration fee: 80€  (Coffee breaks and lunches are included in the registration)
Read More

Designing nanomedicines

Next May 3, will take place in Barcelona, at the Academy of Medical and Health Sciences of Catalonia and the Balearic Island, an informative session and debate about Nanotecnology and Health “Designing Nanomedicines” in wich Prof. Antonio Villaverde, Strategy Director of NANBIOSIS U1. Protein Production Platform (PPP) will give a talk on “Nanobiotechnological approaches to cancer medicine“. Prof. Jesús Martínez de la Fuente, (ICMAB-CSIC / Universidad de Zaragoza – CIBER-BBN) will speak about “the nanorevolution: towards a healthier world“.

The organization of the even has been in charge of Pilar Marco, Scientific Director of NANBIOSIS U2  Custom Antibody Service (CAbS), as a member of the board of directors of the Catalan Society of Medical Biotechnology.

Programe

Read More

Unit 2 Nanbiosis have signed an agreement with a Belgian Enterprise.

U2 unit of Nanbiosis (Custom antibody service) has recently signed a 3-year contract with UNISENSOR S.A. (Liege, Belgium) for producing on a high scale a collection of immunoreagents used in their diagnostic kits.

UNISENSOR S.A. is a SME biotech company that develops on site diagnostic systems for food safety. Unit 2 of NANBIOSIS, coordinated by Nb4D-CSIC holds a research collaboration for more than 7 years developing new bioproducts and transferring knowledge to UNISENSOR S.A. As result of the collaboration several diagnostic kits are nowadays in the market, consequently this contract has been signed with the aim to supply UNISENSOR S.A. with immunoreagents for their diagnostic products. The biomolecules produced by CAbS are completely characterized and respond to quality control criteria required by UNISENSOR S.A.

Read More

NANBIOSIS in three projects funded by CaixaIMPULSE

La Caixa has just presented the twenty projects selected by CaixaImpulse in a call with more than 70 proposals from different research centres, hospitals and universities. CaixaImpulse is an initiative unique in Spain that aims to boost research in biotechnology and life sciences to develop projects that generate value in society.

Among the selected projects there are two coordinated by NANBIOSIS researchers: Pseudomonas aeruginosa diagnosis led by Miriam Corredor Sánchez (Unit 2 of NANBIOSIS) and ISCHEMSURG, led by Monica Mir (Unit 7 of NANBIOSIS). In addition, the project ExoLiver, in which participates Rosa Villa and the research group coordinating Unit 8 of NANBIOSIS, has been also granted.

NANBIOSIS in three projects funded by CaixaIMPULSE.
Read More

Unit 2 of NANBIOSIS participates in the FoodSmartPhone project of Marie Sklodowska Curie.

The Nb4D group of CSIC, coordinator of Unit 2 of NANBIOSIS led by Pilar Marco has joined the consortium for the FoodSmartPhone project funded by the Marie Sklodowska Curie Research Program. The Marie Sklodowska-Curie Actions (MSCA) support training in research and professional development aimed at innovation skills.

The objective of the project is to develop a smartphone-based diagnostic and detection tool for simplified quick pre-selection of food quality and safety parameters. This is because food safety and quality tests are currently inefficient, expensive and ineffective and can not guarantee food safety for all consumers or prevent possible incidents of food fraud.

FoodSmartPhone offers an opportunity for a doctorate that covers all aspects of smartphone-based detection tools, as well as a wealth of scientific knowledge as well as innovation and transfer.

The Nb4D group will act as leader of work package For more information 1 which aims to develop new concepts of ligand binding assay. The group will host two ESRs (Early Stage Researchers) and will also organize training events and an advanced PhD course for the production of haptens and bioreceptors.

For more information

Unit 2 of NANBIOSIS participates in the FoodSmartPhone project of Marie Sklodowska Curie.
Read More